Date: Thursday 12th December 2024
Time: 16:00-17:00 GMT | 17:00-18:00 CET | 11:00-12:00 EST
Presenters: Andrew Grieve and Zhiwei Zang
Chair: Jenny Devenport
Location: Online via Zoom
Who is this event intended for? Anyone interested in hearing more about group sequential designs
What is the benefit of attending? To gain a better understanding about group sequential designs, the applications, the advantages and the disadvantages.
Registration
This event is free to attend for both Members of PSI and Non-Members.
To register, please click here.
Please join us to hear Andrew Grieve and Zhiwei Zhang present their recent work. The webinar will be chaired by Jenny Devenport.
Post presentation discussions to information to follow.
PSI Journal Club is sponsored by Wiley. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
The meetings are open to both PSI and non-PSI members.
|
Speaker |
Biography |
|
|
A Ph.D. statistician by training, Jenny Devenport has more than 20 years of experience driving decisions in the healthcare industry including device /pharmaceutical development, quality monitoring and program evaluation in public health, and practice management in occupational healthcare systems. She aims to ask the right questions and develop optimal solutions to get patients the best care. She champions scientific curiosity, use of diverse data sources, effective measurement, and meticulous study design. As a leader and coach, she gets people to exceed themselves by leaving their comfort zones, appreciating their strengths, building strategic collaborations, forming extensive personal networks, and aiming for impact locally and globally. |
|
|
Andrew P. Grieve is a Visiting Professor at King’s College London having recently retired from the position of Research Fellow in the Statistical Innovation group at UCB Pharma. He is a former Chair of PSI (Statisticians in the Pharmaceutical Industry) and a past-President of the Royal Statistical Society. He has over 45 years of experience as a biostatistician working in the pharmaceutical industry and academia. He has been active in the majority of areas of pharmaceutical R&D in which statistical methods and statisticians are intimately involved including drug discovery, pre-clinical toxicology, pharmaceutical development, pharmacokinetics and pharmacodynamics, phase I-IV of clinical development, manufacturing, health economics and clinical operations. Since the early 1980s he has promoted the use of Bayesian methods in pharmaceutical R&D and his statistical research has been primarily concerned with the implementation of Bayesian ideas and techniques. Latterly he has concentrated on the design and implementation of Bayesian adaptive trials, and the Probability of Success (PoS) of studies and drug development programs. He has published over 140 articles and is the author of two books. He has been an invited speaker at national and international conferences on over 300 occasions. |
|
|
Zhiwei Zhang is a senior director at Gilead Sciences. Before joining Gilead, he worked in academia and government agencies, including FDA and NIH. His research interests include causal inference and clinical trial design and analysis. Dr. Zhang has published over 100 research articles, mostly in statistical journals. He is an elected fellow of the American Statistical Association. |
